BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/9/2022 12:48:14 PM | Browse: 430 | Download: 1176
 |
Received |
|
2021-12-29 13:36 |
|
Peer-Review Started |
|
2021-12-29 13:38 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-04-17 01:23 |
|
Revised |
|
2022-05-13 13:43 |
|
Second Decision |
|
2022-07-21 03:10 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-07-26 18:30 |
|
Articles in Press |
|
2022-07-26 18:30 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-07-17 03:41 |
|
Typeset the Manuscript |
|
2022-07-29 11:55 |
|
Publish the Manuscript Online |
|
2022-09-09 12:48 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Advances in postoperative adjuvant therapy for primary liver cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhi-Ming Zeng, Ning Mo, Jie Zeng, Fu-Chao Ma, Yan-Feng Jiang, Hua-Sheng Huang, Xi-Wen Liao, Guang-Zhi Zhu, Jie Ma and Tao Peng |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tao Peng, MD, PhD, Chief Doctor, Professor, Surgeon, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuang Yong Road, Qingxiu District, Nanning 530021, Guangxi Zhuang Autonomous Region, China. pengtaogmu@163.com |
| Key Words |
Adjuvant therapy; Liver cancer; Immunotherapy; Chemotherapy; Targeted therapy |
| Core Tip |
This review discusses the risk factors for recurrence in patients with hepatocellular carcinoma (HCC) radical surgical resection and adjuvant treatment options that may reduce the risk of recurrence and improve overall survival, including local adjuvant therapy (e.g., transcatheter arterial chemoembolization), adjuvant systemic therapy (e.g., molecular targeted agents), and other adjuvant therapies (e.g., antiviral and herbal therapy). Finally, potential research directions that may change the paradigm of adjuvant therapy for HCC are analyzed. |
| Publish Date |
2022-09-09 12:48 |
| Citation |
Zeng ZM, Mo N, Zeng J, Ma FC, Jiang YF, Huang HS, Liao XW, Zhu GZ, Ma J, Peng T. Advances in postoperative adjuvant therapy for primary liver cancer. World J Gastrointest Oncol 2022; 14(9): 1604-1621 |
| URL |
https://www.wjgnet.com/1948-5204/full/v14/i9/1604.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v14.i9.1604 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
